{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Myeloma: How to Fit the Three New Drugs into Clinical Practice
Activity Steps
{{ evaluation.question.text }}
{{choice.text}}
{{evaluation.answerSet[0].text}}
Purpose of Activity
To provide information on current recommendations for treating myeloma, including the use of three recently-approved drugs.Learning Objectives
After completing this continuing education activity you will be able to:
- Identify issues related to the staging and treatment of myeloma, including the use of immunomodulating agents (IMiDs) and the new monoclonal antibodies, daratumumab and elotuzumab.
- Explain the use of the new proteasome inhibitor, ixazomib, for treating myeloma.
Disclosures
All staff and planners, including spouses/partners (if any), in any position to control the content of this CME activity have disclosed that they have no financial relationships with, or financial interests in, any commercial companies pertaining to this educational activity.
Price:
$17.95
Credits:
- ANCC 1.5 CH
- DC - BON 1.5 CH
- KY-BON 1.5 CH
- GA - BON 1.5 CH
Lippincott Williams & Wilkins is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749. Lippincott Williams & Wilkins is also an approved provider of continuing nursing education by the District of Columbia Board of Nursing, #50-1223, Florida Board of Nursing, #50-1223, and Georgia Board of Nursing, #50-1223. Your certificate is valid in all states.
{{ evaluation.question.text }}
{{choice.text}}
{{evaluation.answerSet[0].text}}
Test Code: OT0116
Published: Jan 2016
Expires: 12/31/2026
Sources:
Oncology Times
Required Passing Score: 7/10 (70%)
Specialties:
Oncology